Cargando…
An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer
BACKGROUND: Men with metastatic castration-resistant prostate cancer (mCRPC) are living longer, therefore optimizing health-related quality of life (HRQL), as well as survival outcomes, is important for optimal patient care. The aim of this study was to assess the HRQL in patients with mCRPC receivi...
Autores principales: | Thiery-Vuillemin, A., Fizazi, K., Sartor, O., Oudard, S., Bury, D., Thangavelu, K., Ozatilgan, A., Poole, E.M., Eisenberger, M., de Bono, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7980065/ https://www.ncbi.nlm.nih.gov/pubmed/33740734 http://dx.doi.org/10.1016/j.esmoop.2021.100089 |
Ejemplares similares
-
Post Hoc Health‐Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies
por: Thiery‐Vuillemin, Antoine, et al.
Publicado: (2021) -
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
por: Mehra, Niven, et al.
Publicado: (2018) -
Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
por: Delanoy, Nicolas, et al.
Publicado: (2021) -
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
por: Suzuki, Hiroyoshi, et al.
Publicado: (2021) -
Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as
prognostic markers in patients with metastatic castration-resistant prostate
cancer
por: Meisel, Alexander, et al.
Publicado: (2022)